The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
Chronic kidney disease (CKD) affects around 10% of the global population and is most often caused by diabetes. Diabetes with CKD (diabetic kidney disease, DKD) is a progressive condition that may cause kidney failure and which contributes significantly to the excess morbidity and mortality in these...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2022-07-01
|
| Серія: | Therapeutic Advances in Endocrinology and Metabolism |
| Онлайн доступ: | https://doi.org/10.1177/20420188221112490 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|